JACK-MA/ALIBABA
29.3.2020 07:00:09 CEST | Business Wire | Press release
The Jack Ma Foundation and the Alibaba Foundation today announced donations of essential medical supplies to seven more countries, namely Azerbaijan, Bhutan, India, Kazakhstan, Kyrgyzstan, Uzbekistan and Vietnam.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200328005024/en/
Collectively, these seven countries will receive a total of 1.7 million face masks, 165,000 test kits as well as protective clothing and medical equipment such as ventilators and forehead thermometers. With this announcement, the two Foundations have now donated essential medical supplies to 23 Asian countries totalling 7.4 million masks; 485,000 test kits; 100,000 sets of protective clothing along with other medical equipment.
The first batch of medical supplies for India arrived in Delhi last night and were received by the Indian Red Cross Society. Similar to the arrangement with the Italian Red Cross Society, the Indian charity will facilitate the distribution of these supplies in the country. The donations are expected to reach other countries in the coming days.
Mr. Neel Kamal Singh, Deputy Secretary, Indian Red Cross Society took receipt of the donations from Mr. Vivek Sehgal, Manager, Alibaba Cloud India, acting on behalf of the Jack Ma Foundation and the Alibaba Foundation. Ms. Ma Jia, Deputy Chief of Mission of the Embassy of China in India, was also present to show the embassy’s support towards this humanitarian initiative.
“Government of India has taken extensive steps to manage the COVID-19 situation. To supplement the efforts of government, Indian Red Cross has mobilised first tranche of supplies consisting of facemasks, protective body suits and essential medical equipment. This consignment, which was received yesterday, has been donated by Jack Ma Foundation and Alibaba Foundation. Indian Red Cross appreciates their magnanimity at this difficult juncture,” said Mr. R.K Jain, IAS (Rtd), Secretary General, Indian Red Cross .
“We are one with the global community in the intense battle to protect all families against Covid-19. We are committed to doing everything we can to make a difference, most importantly by sourcing these supplies and overcoming logistical challenges to get the medical supplies to where they are needed as fast as we can,” said the Jack Ma Foundation .
These donations are among a number of aid initiatives from the Alibaba Foundation and Jack Ma Foundation to support the areas of the world affected by the Covid-19 crisis, sourcing and delivering various types of medical supplies to countries across Asia, North America, Latin America, Europe and Africa. The donation by the two foundations to Vietnam is in addition to the recent donation by Lazada Group, Alibaba Group’s local e-commerce business unit in Southeast Asia.
More initiatives and donations may be announced in the coming days and weeks.
The Jack Ma Foundation and the Alibaba Foundation also supported the publication of a handbook with key lessons and experience from doctors, healthcare workers, and hospital administrators at the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), who were on the frontline of COVID-19 treatment in China and crucial to slowing its spread. The handbook is available for global medical health professionals at https://covid-19.alibabacloud.com/ .
Follow @JackMa and @foundation_ma on Twitter for the latest efforts of Jack Ma Foundation and Alibaba Foundation to support the global fight against COVID-19.
About Jack Ma Foundation
Established by Jack Ma, the founder of Alibaba Group, the Jack Ma Foundation was founded on 15 December 2014 and has been focusing on education, entrepreneurship, women’s leadership, and the environment. The Foundation aspires to be a reliable, participative, and sustainable philanthropic organization. The Jack Ma Foundation has so far supported projects worldwide including the Jack Ma Rural Education Program, the Africa Netpreneur Prize Initiative, the Ma & Morley Scholarship Program, and Jordan's Queen Rania Foundation. Additionally, the Foundation has also funded a number of projects in its priority areas. The Jack Ma Foundation is committed to empowering rural educators, entrepreneurs, rural children, young start-ups, and women to equip them for the future and to help build a happier, healthier, more sustainable and more inclusive society.
About Alibaba Foundation
The Alibaba Foundation, established in December 2011, aims to create a culture that encourages people to get involved in philanthropy, make it sustainable and genuinely contribute to civil society and nature. Its key funding aspects include water protection, environmental awareness promotion and development of green organizations. Alibaba Group is committed to devoting a percentage of its annual income to the Alibaba Foundation to ensure stable long-term funding that will allow for timely response in the event of natural disasters or expansion of philanthropic projects.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200328005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom